Novo Nordisk's Sogroya Receives Positive CHMP Opinion for Idiopathic Short Stature in Europe — Novo Nordisk

Event summary

Novo Nordisk's Sogroya (somapacitan) received a positive CHMP opinion for treating idiopathic short stature (ISS) in children in Europe.
If approved, Sogroya would be the first and only growth hormone treatment approved for ISS in the EU.
The CHMP recommendation follows previous approvals for Sogroya in treating short stature in children born small for gestational age (SGA) and Noonan Syndrome.
The European Commission's decision on marketing authorization is expected later in 2026.
Sogroya is a once-weekly, long-acting growth hormone analogue using albumin-binding technology.

The big picture

Novo Nordisk's positive CHMP opinion for Sogroya in treating idiopathic short stature marks a strategic expansion into a previously underserved pediatric market. The approval, if finalized, would position Novo Nordisk as the sole provider of a growth hormone treatment for ISS in Europe, addressing a condition affecting up to 3% of children worldwide. This move aligns with broader industry trends towards specialized treatments for rare and under-recognized conditions, potentially setting a precedent for future regulatory approvals in similar therapeutic areas.

What we're watching

Regulatory Approval: Whether the European Commission will approve Sogroya for ISS, expanding Novo Nordisk's market reach in pediatric growth hormone treatments.
Market Exclusivity: How Novo Nordisk will leverage Sogroya's status as the first approved treatment for ISS in the EU to gain market share.
Treatment Access: The pace at which Sogroya becomes available to children with ISS, addressing the current lack of recognized treatment options.